Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 2021 Year End Financial Results
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(56)
•••
Comment by RalphRalphon Jun 28, 2021 8:46am
158 Views
Post# 33458812

RE:RE:2021 Year End Financial Results

RE:RE:2021 Year End Financial Results
Some good for sure, but there are some concerning aspects as well.  Note the P3 delay.  Also, why has 352 not progressed further?  It's perplexing that amidst all other initiatives, they've not been able to advance 352.  Before they add more preclinical IP to the pipeline (especially in crowded areas like IBD & Alzheimer's), perhaps they could focus on progressing 340/352.  A company with a bunch of preclinical IP is generally not as valuable as a similar company with validated clinical data on 2-3 molecules.  IP is only useful if you can move it forward in the clinic.
 
And still no deal re: Citagenix.  The company has definitely taken some good steps, but it would be nice to get some kind of explanation as to why long-discussed goals (Cita, 352 advancement, etc) have not been accomplished.



Forestview wrote: Financials look strong.  Good summary.  Exciting times ahead.  

GameChangerBet wrote: https://www.businesswire.com/news/home/20210628005228/en/Antibe-Therapeutics-Reports-2021-Year-End-Financial-Results-and-Business-Highlights




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities